This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Cholesterol and recurrent events trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The CARE trial was a study of the use of pravastatin for the secondary prevention of coronary events.


  • 4000 patients aged 21-75 years with a past history of myocardial infarction and a plasma total cholesterol below 6.2 mmol/l

Trial design:

  • patients randomised to placebo or pravastatin 40 mg per day for 5 years


  • pravastatin reduced mean plasma cholesterol concentration by 20%
  • LDL cholesterol was reduced by 28%
  • the risk of either death from CHD or non-fatal myocardial infarction was reduced by 24% in the pravastatin group
  • the pravastatin group showed a 31% reduction in risk of stroke and a 27% reduction in need for either coronary artery bypass grafting or coronary angioplasty
  • this trial revealed survival benefit gains for a total cholesterol of 4.8 mmol/l or below


  • Drug and Therapeutics Bulletin (1996), 34 (12), 89-93.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.